462 related articles for article (PubMed ID: 22914579)
1. Estimating the cost-effectiveness of needle-syringe programs in Australia.
Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
[TBL] [Abstract][Full Text] [Related]
2. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
3. Individual-level syringe coverage among Needle and Syringe Program attendees in Australia.
Iversen J; Topp L; Wand H; Maher L
Drug Alcohol Depend; 2012 May; 122(3):195-200. PubMed ID: 22071120
[TBL] [Abstract][Full Text] [Related]
4. Syringe exchange in the United States: a national level economic evaluation of hypothetical increases in investment.
Nguyen TQ; Weir BW; Des Jarlais DC; Pinkerton SD; Holtgrave DR
AIDS Behav; 2014 Nov; 18(11):2144-55. PubMed ID: 24824043
[TBL] [Abstract][Full Text] [Related]
5. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis.
Kwon JA; Iversen J; Maher L; Law MG; Wilson DP
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):462-9. PubMed ID: 19387355
[TBL] [Abstract][Full Text] [Related]
6. Is Vancouver Canada's supervised injection facility cost-saving?
Pinkerton SD
Addiction; 2010 Aug; 105(8):1429-36. PubMed ID: 20653622
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.
Sweeney S; Ward Z; Platt L; Guinness L; Hickman M; Hope V; Maher L; Iversen J; Hutchinson SJ; Smith J; Ayres R; Hainey I; Vickerman P
Addiction; 2019 Mar; 114(3):560-570. PubMed ID: 30674091
[TBL] [Abstract][Full Text] [Related]
8. Needle exchange programs: an economic evaluation of a local experience.
Gold M; Gafni A; Nelligan P; Millson P
CMAJ; 1997 Aug; 157(3):255-62. PubMed ID: 9269195
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
10. Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil project.
Caiaffa WT; Mingoti SA; Proietti FA; Carneiro-Proietti AB; Silva RC; Lopes AC; Doneda D
J Urban Health; 2003 Mar; 80(1):106-14. PubMed ID: 12612100
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
[TBL] [Abstract][Full Text] [Related]
12. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010.
Wiessing L; Likatavicius G; Hedrich D; Guarita B; van de Laar MJ; Vicente J
Euro Surveill; 2011 Dec; 16(48):. PubMed ID: 22172300
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.
Long EF; Brandeau ML; Galvin CM; Vinichenko T; Tole SP; Schwartz A; Sanders GD; Owens DK
AIDS; 2006 Nov; 20(17):2207-15. PubMed ID: 17086061
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
[TBL] [Abstract][Full Text] [Related]
15. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
van Beek I; Chronister KJ
Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of harm reduction.
Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
[TBL] [Abstract][Full Text] [Related]
17. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
Falster K; Kaldor JM; Maher L;
J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
[TBL] [Abstract][Full Text] [Related]
19. Needle and syringe programs in Yunnan, China yield health and financial return.
Zhang L; Yap L; Xun Z; Wu Z; Wilson DP
BMC Public Health; 2011 Apr; 11():250. PubMed ID: 21507267
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings.
Islam M; Wodak A; Conigrave KM
Int J Drug Policy; 2008 Dec; 19(6):436-41. PubMed ID: 17766100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
